Dialog Box

Meet the ARC Portal Team

Professor Clare Scott MBBS, PhD, FRACP, FAHMS

Principal Investigator, Australian Rare Cancer Portal

Professor Clare Scott is the Joint Division Head of the Clinical Translation Centre and Head of the Ovarian and Rare Cancers Laboratory at the Walter and Eliza Hall Institute of Medical Research (WEHI). Dr Scott is the Professor of Gynaecological Cancer at The University of Melbourne and is a Medical Oncologist at the Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals. She has 20 years’ experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Professor Scott has been Principal Investigator for more than ten cancer clinical trials of targeted therapy. In the laboratory, Professor Scott has developed ovarian and other rare cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance.

Professor Scott has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. Professor Scott was awarded the Sir Edward Dunlop Cancer Research Fellowship from Cancer Council Victoria (2012) and a Clinical Research Fellowship from the Victorian Cancer Agency (2011, 2017). In 2018, she was recognized for her work in gynaecological cancers with the Jeannie Ferris Recognition Award from Cancer Australia.

Professor Scott is currently Chair, Clinical Oncology Society Australia (COSA) Rare Cancer Group; Chair, International Rare Cancer Initiative (IRCI) Board; Co-Chair, Gynaecologic Cancer Intergroup (GCIG) Rare Tumour Committee; and Director, Australia New Zealand Gynaecology Oncology Group (ANZGOG), providing valuable insights nationally and internationally regarding the treatment of and research into rare cancers.

Professor Scott’s contribution to the community is reflected by her instigation of and participation in the WEHI’s Consumer Advisory Panel, now a leading example of involvement of the public in a Medical Research Institute. Dr Scott also leads CART-Wheel.org, a BioGrid Australia platform for consumer data entry for people with a rare cancer who would like to participate in data collection for research.


Professor David Goldstein MBBS FRCP (UK) FRACP

Co-Lead Investigator, Australian Rare Cancer Portal

Professor Goldstein is a conjoint clinical professor. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobilary and upper GI malignancy and renal cell carcinoma and lymphoma. He has been a Chief or Principal Investigator on $26,000,000 peer reviewed funded grants .

His activity over many years in one of the least common cancers and least studied, until recently, in the GI area – pancreas cancer, as well as GIST and biliary cancers gives him great insight into the challenges of approaching a suite of rare cancers. He has also been involved in several large scale epidemiologic studies, the most recent looking at pancreatic cancer. He has contributed to pivotal data resulting in PBS changes in approval for adjuvant gemcitabine in pancreas cancer, imatinib in metastatic and adjuvant GIST and first line nab-paclitaxel in pancreatic cancer.

Professor Goldstein is the Director of the UNSW Translational Cancer Research Network, a $6,000,000 CINSW funded program. He is the adult program leader of the UNSW National Cancer Survivors Centre and is involved with a research program associated with survivorship issues. As part of this activity, he is the Chief Investigator of a Cancer Institute NSW translational program grant of $3,100,000 to study the impact of chemotherapy induced peripheral neuropathy.

Professor Goldstein also actively participates in three laboratory research programs dealing with stromal biology, pancreas drug resistance and modeling optimal targeted therapies in sarcoma.

Professor Goldstein has been a member of the Australian Gastro-Intestinal Trials Group Scientific Advisory Committee for the last 12 years, was a board member and treasurer of the Gastro-Intestinal Cancer Institute for nine years, the longest serving president of the Clinical Oncology Society of Australia (COSA) and a member of both the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research. He serves on ASCO international committees engaged in supporting enhanced cancer service delivery in less developed countries.

Dr Damien Kee MBBS, DMedSc, FRACP

Medical Oncologist, Australian Rare Cancer Portal

Dr Damien Kee is a medical oncologist based at the Austin Hospital, where he leads the melanoma and skin cancer oncology team, as well as at the Peter MacCallum Cancer Centre. He has been the principal investigator of clinical trials encompassing targeted and immune-based therapies and cancer genomics. Damien is also a senior clinician researcher in the Rare Cancers Laboratory at the Walter and Eliza Hall Institute of Medical Research and the Deputy Chair of the Clinical Oncology Society of Australia Rare Cancers Group. He chairs a national molecular tumour board for patients with rare cancers.

Dr Kee’s research focus is on developing national platforms and clinical trials to enhance outcomes for patients with rare cancers. Apart from the Australian Rare Cancer Portal, he is involved in the Stafford Fox Rare Cancer Program and works closely with rare cancer consumers through the www.cart-wheel.org project, the Cancer Council’s Rare Cancers Group, and Rare Cancers Australia.

Dr Reece Caldwell BSc (Biomedical Science), MBBS, FRACP

Research Fellow, Australian Rare Cancer Portal

Dr Reece Caldwell completed his medical degree at the University of Queensland and residency at the Royal Brisbane and Women's Hospital. Upon completing specialist training in Medical Oncology, Reece relocated to London and completed a Fellowship in Early Drug Development at the Royal Marsden Hospital.

 He has an interest in biomarker driven trial design. He then joined the Gynaecology Unit at Imperial College as a Consultant Medical Oncologist, based at both Hammersmith and Charing Cross Hospitals, with a focus on recruitment of patients to ovarian cancer clinical trials and holistic patient care. Reece is passionate about involving all members of health care teams to provide patient centred care and palliation.

Having returned to Australia, Reece has now joined the ARCP team as a Clinical Research Fellow. Having trained in regional centres, Reece is committed to helping improve access for all patients with rare cancers to clinical trials and evidence based best practice.

Dr Chloe Georgiou MBBS, BMedSc

Research Fellow, Australian Rare Cancer Portal

Dr Chloe Georgiou is the inaugural Clinical Trials Fellow at Bendigo Health in Victoria. She completed her undergraduate medical degree through the University of Melbourne, and is currently studying a Master of Cancer Sciences. Her research interests include healthcare service delivery, database collation to assess real-world patient outcomes, and development of protocols and predictive tools to minimise toxicity and maximise treatment response.

Growing up in regional Victoria she developed an understanding of geographical limitations to cancer care. She is passionate about quality care for all cancer patients, especially access to treatments and clinical trials without unnecessary travel or financial burden.

As a Fellow with the Australian Rare Cancer Portal Chloe will respond to patient referrals, co-ordinate expert responses where requested, and assist in maintaining a database designed to improve the understanding of rare cancer in Australia.



Dr Lia Papadopoulos MBBS (Hons), FRACP

Research Fellow, Australian Rare Cancer Portal

Dr Lia Papadopoulos completed her medical degree at Monash University and completed her Medical Oncology training in Melbourne at Austin Hospital, St Vincents' Hospital and Eastern Health. After completing specialist training Lia joined Eastern Health as the Genito-urinary trials fellow and Consultant Medical Oncologist. She is currently post-graduate study in Health Professional Education. Her clinical interests include breast, genito-urinary, and lung malignancies.

As a Research Fellow for the Australian Rare Cancer Portal, Lia will strive to deliver quality, research-driven care to Australians with rare cancers. She believes all patients should have equitable access to comprehensive cancer care including cutting-edge genomic assessment or clinical trials, no matter their financial resources or geographical location.


Dr Rebecca Tay MBBS (Hons) FRACP

Research Fellow, Australian Rare Cancer Portal

Dr Rebecca Tay is Medical Oncologist at the Royal Hobart Hospital in Tasmania. She has a key interest in the management of thoracic malignancies following completion of a two-year Clinical Research Fellowship at The Christie NHS Foundation Trust in Manchester; one of the largest cancer centres in Europe and a Cancer Research UK (CRUK) ‘Lung Cancer Centre of Excellence’. Dr Tay’s clinical research focuses on assessing the utility of lung cancer biomarkers for clinical use and ‘real world’ outcomes.

As a Research Fellow for the Australian Rare Cancer Portal, Dr Tay remains committed to delivering patient-centred, research-driven care to improve cancer outcomes, particularly for patients with a rare cancer diagnosis in regional Australia.

Dr Michael Samuel Krasovitsky MBBS (Hons I), BA (Langs) (Hons I), MIPH

Research Fellow, Australian Rare Cancer Portal

Dr Michael Krasovitsky is a medical oncology fellow at St George Hospital and Prince of Wales Hospital, NSW. His key clinical interests include the management of breast, gynaecological and central nervous system malignancies. He has been involved in the establishment of a structured oncofertility and oncosexuality program, and is a strong advocate for reproductive planning for individuals undergoing cancer treatment. He also has an interest in the intersection between COVID-19 and cancer, and is currently involved in a number of research endeavours in this field. As part of his further education, Dr Krasovitsky is exploring issues surrounding universal access to BRCA1 and BRCA2 testing among Australian Jewish women.

Dr Krasovitsky prides himself on delivering best practice, up to date, compassionate care to his patients, and is committed to ensuring that all patients, no matter their geographic location, have access to a comprehensive cancer team. As part of the ARC Portal team, Dr Krasovitsky’s main roles include coordinating specialist reviews, liaising with patients and referrers, and facilitating expert pathology and genomic assessment. He is passionate about working with patients affected by rare cancers, and strives to ensure that the best quality care can be delivered in a timely manner to each and every individual affected by a rare cancer.


Allison Bourne PhD (Biochemistry), MClinEpid, BA/BSc (Hons)
Administrative  Officer, Australian Rare Cancer Portal

Allison Bourne is the administrative assistant for the ARC Portal. Allison holds a PhD in Biochemistry and a Masters in Clinical Epidemiology. Allison’s most recent experience includes coordinating clinical trials and conducting research studies across a range of disease areas in both the hospital and university setting.

As the administrative officer for the Portal, Allison will be able to assist with any registration and referral queries or issues.




Referrals to the Australian Rare Cancer Portal are initially reviewed by a member of our team. Depending on the nature of the referral, the team will manage it directly or request assistance from a member of our network of rare cancer specialists.



Refer a patient

Register and refer a patient to the ARC portal to improve the quality of care and outcomes of patients with a rare cancer diagnosis

ReferContact Us

Donate